CN107937423A - 用于治疗变态反应的核酸 - Google Patents

用于治疗变态反应的核酸 Download PDF

Info

Publication number
CN107937423A
CN107937423A CN201710999629.5A CN201710999629A CN107937423A CN 107937423 A CN107937423 A CN 107937423A CN 201710999629 A CN201710999629 A CN 201710999629A CN 107937423 A CN107937423 A CN 107937423A
Authority
CN
China
Prior art keywords
ser
gly
ala
asn
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710999629.5A
Other languages
English (en)
Chinese (zh)
Inventor
威廉·赫尔
特瑞·海兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomic Therapeutics Inc
Original Assignee
Immunomic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics Inc filed Critical Immunomic Therapeutics Inc
Priority to CN201710999629.5A priority Critical patent/CN107937423A/zh
Publication of CN107937423A publication Critical patent/CN107937423A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • A61K39/36Allergens from pollen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34Antigenic peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/35Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CN201710999629.5A 2012-06-15 2012-06-15 用于治疗变态反应的核酸 Pending CN107937423A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710999629.5A CN107937423A (zh) 2012-06-15 2012-06-15 用于治疗变态反应的核酸

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710999629.5A CN107937423A (zh) 2012-06-15 2012-06-15 用于治疗变态反应的核酸
CN201280075163.5A CN104519896B (zh) 2012-06-15 2012-06-15 用于治疗变态反应的核酸
PCT/US2012/042552 WO2013187906A1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280075163.5A Division CN104519896B (zh) 2012-06-15 2012-06-15 用于治疗变态反应的核酸

Publications (1)

Publication Number Publication Date
CN107937423A true CN107937423A (zh) 2018-04-20

Family

ID=49758576

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710999629.5A Pending CN107937423A (zh) 2012-06-15 2012-06-15 用于治疗变态反应的核酸
CN201280075163.5A Active CN104519896B (zh) 2012-06-15 2012-06-15 用于治疗变态反应的核酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280075163.5A Active CN104519896B (zh) 2012-06-15 2012-06-15 用于治疗变态反应的核酸

Country Status (20)

Country Link
US (3) US9744230B2 (https=)
EP (2) EP3808361A1 (https=)
JP (1) JP5807994B2 (https=)
KR (2) KR102386481B1 (https=)
CN (2) CN107937423A (https=)
AU (3) AU2012382406B2 (https=)
BR (1) BR112014031327B1 (https=)
CA (1) CA2876824C (https=)
CY (1) CY1123769T1 (https=)
DK (1) DK2861240T3 (https=)
ES (1) ES2831723T3 (https=)
HR (1) HRP20201815T1 (https=)
HU (1) HUE052481T2 (https=)
IL (4) IL236174B (https=)
LT (1) LT2861240T (https=)
PL (1) PL2861240T3 (https=)
PT (1) PT2861240T (https=)
RS (1) RS61098B1 (https=)
SI (1) SI2861240T1 (https=)
WO (1) WO2013187906A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112119161A (zh) * 2018-05-11 2020-12-22 安斯泰来制药株式会社 用于甲壳类过敏治疗的核酸
CN113631231A (zh) * 2019-03-13 2021-11-09 普梭梅根公司 用于过敏治疗的基于表位的方法和克罗恩病的抑制剂

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160185831A1 (en) * 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
AU2012382406B2 (en) * 2012-06-15 2017-12-07 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
PL2914286T3 (pl) 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof
WO2015200357A2 (en) * 2014-06-23 2015-12-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
TWI752930B (zh) 2015-12-23 2022-01-21 德商梅迪基因免疫治療公司 抗原特異性tcr的新生成
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
IL270024B2 (en) * 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination
KR20200016224A (ko) * 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
WO2019018529A1 (en) 2017-07-18 2019-01-24 Before Brands, Inc. METHODS OF MAKING MIXED ALLERGEN COMPOSITIONS
CN111936856A (zh) * 2018-04-06 2020-11-13 Sls生物有限公司 新型免疫球蛋白e的表位、与其结合的抗体及包括所述抗体的用于分析试料中免疫球蛋白e的试剂盒
US20210163957A1 (en) 2018-05-11 2021-06-03 Astellas Pharma Inc. Nucleic acid for treating mite allergy
EP3793595A1 (en) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
AU2020213085A1 (en) 2019-01-23 2021-08-12 Société des Produits Nestlé S.A. Methods for making mixed allergen compositions
US12150461B2 (en) * 2021-05-04 2024-11-26 Sovida Solutions Ltd. Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
WO2023013785A1 (ja) * 2021-08-06 2023-02-09 花王株式会社 Snareを活用した核酸構築物
FI131854B1 (en) 2023-05-29 2026-01-12 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic activity and greater survival

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011512A2 (en) * 1992-11-12 1994-05-26 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
WO2001076642A1 (en) * 2000-04-07 2001-10-18 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines
WO2002080851A2 (en) * 2001-04-05 2002-10-17 The Johns Hopkins University Chimeric vaccines
US20060216315A1 (en) * 2005-03-16 2006-09-28 Yoo Tai J Cockroach allergen gene expression and delivery systems and uses
CN102186880A (zh) * 2008-09-10 2011-09-14 Ith免疫治疗控股股份公司 炎症的治疗

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD335810S (en) 1990-07-02 1993-05-25 Dick-Ming Asien Handle for luggage or similar article
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6090386A (en) 1991-07-12 2000-07-18 Griffith; Irwin J. T cell peptides of the CRX JII allergen
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
JP3649460B2 (ja) 1993-11-05 2005-05-18 明治乳業株式会社 スギ花粉アレルゲンCry j IIエピトープ
GB9516760D0 (en) 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
EP0873135B1 (en) 1995-12-29 2009-07-22 The University of Arkansas Peanut allergens and methods
CN101307095A (zh) 1996-06-14 2008-11-19 明治乳业株式会社 T细胞表位肽
AU2002306850A1 (en) 2001-03-16 2002-10-03 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
US20060003148A1 (en) 2004-06-30 2006-01-05 Zwynenburg James L Interlocking polymeric foam floor underlayment and process for making
WO2006138435A2 (en) 2005-06-16 2006-12-28 Mount Sinai School Of Medicine Methods for enhancing immune responses
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
JPWO2007024026A1 (ja) * 2005-08-25 2009-03-05 明石 満 T細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子
US20080006554A1 (en) 2006-07-07 2008-01-10 Medtronic Vascular, Inc. Packaging assembly for a catheter
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
AU2012382406B2 (en) * 2012-06-15 2017-12-07 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
US11826423B2 (en) * 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
IL270024B2 (en) * 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011512A2 (en) * 1992-11-12 1994-05-26 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
WO2001076642A1 (en) * 2000-04-07 2001-10-18 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines
WO2002080851A2 (en) * 2001-04-05 2002-10-17 The Johns Hopkins University Chimeric vaccines
US20060216315A1 (en) * 2005-03-16 2006-09-28 Yoo Tai J Cockroach allergen gene expression and delivery systems and uses
CN102186880A (zh) * 2008-09-10 2011-09-14 Ith免疫治疗控股股份公司 炎症的治疗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FAR IBA KARAMLOO ET AL.: "Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes", 《EUR. J. IMMUNOL.》 *
蔡访勤: "免疫反应引起组织损伤的机理", 《河南医药》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112119161A (zh) * 2018-05-11 2020-12-22 安斯泰来制药株式会社 用于甲壳类过敏治疗的核酸
CN113631231A (zh) * 2019-03-13 2021-11-09 普梭梅根公司 用于过敏治疗的基于表位的方法和克罗恩病的抑制剂

Also Published As

Publication number Publication date
BR112014031327B1 (pt) 2022-02-01
AU2019250227A1 (en) 2019-11-07
JP2015521467A (ja) 2015-07-30
WO2013187906A1 (en) 2013-12-19
IL270261B (en) 2021-03-25
US9744230B2 (en) 2017-08-29
ES2831723T3 (es) 2021-06-09
HRP20201815T1 (hr) 2021-02-19
DK2861240T3 (da) 2020-09-28
CA2876824C (en) 2020-07-21
IL270262A (en) 2019-12-31
RS61098B1 (sr) 2020-12-31
SI2861240T1 (sl) 2021-04-30
KR20200047792A (ko) 2020-05-07
IL236174A0 (en) 2015-01-29
CA2876824A1 (en) 2013-12-19
PL2861240T3 (pl) 2021-07-05
AU2012382406B2 (en) 2017-12-07
BR112014031327A2 (pt) 2017-06-27
PT2861240T (pt) 2020-11-09
AU2019250227B2 (en) 2021-10-21
KR102107646B1 (ko) 2020-05-08
US20220081474A1 (en) 2022-03-17
KR102386481B1 (ko) 2022-04-14
AU2012382406A2 (en) 2015-04-16
IL270260B (en) 2020-08-31
EP2861240A4 (en) 2016-03-16
JP5807994B2 (ja) 2015-11-10
EP2861240B1 (en) 2020-09-09
KR20150032286A (ko) 2015-03-25
EP3808361A1 (en) 2021-04-21
HUE052481T2 (hu) 2021-04-28
CN104519896B (zh) 2017-11-10
IL236174B (en) 2019-11-28
US20180009857A1 (en) 2018-01-11
LT2861240T (lt) 2021-01-25
AU2018200625B2 (en) 2019-09-19
CN104519896A (zh) 2015-04-15
AU2012382406A1 (en) 2014-12-18
AU2018200625A1 (en) 2018-02-15
EP2861240A1 (en) 2015-04-22
US10072053B2 (en) 2018-09-11
CY1123769T1 (el) 2022-05-27
US20160271245A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
KR102386481B1 (ko) 알레르기 치료용 핵산
EP3976075A1 (en) Modified adenoviruses
JP2008500064A (ja) 可変性リンパ球受容体、その関連ポリペプチドおよび核酸、ならびにその使用
IL296854A (en) Antigen-encoding cassettes
AU2021247302A1 (en) Infectious disease antigens and vaccines
JP2021502115A (ja) 非構造タンパク質を含むジカウイルスキメラポリエピトープ、及び免疫原性組成物におけるその使用
US20160185831A1 (en) Nucleic acids for treatment of allergies
Doan et al. Immunization-induced antigen archiving enhances local memory CD8+ T cell responses following an unrelated viral infection
CN115715198A (zh) 新型的基于沙门氏菌的冠状病毒疫苗
Shen et al. DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice
HK1253363A1 (zh) 用於治疗变态反应的核酸
JP2017079742A (ja) アレルギー治療のための核酸
AU2019268022A1 (en) Nucleic acid for treating mite allergy
Tamburini et al. Vaccine-induced antigen archiving enhances local memory CD8+ T cell responses following an unrelated viral infection
HK40042839A (en) Nucleic acid for treating mite allergy
KR20210007981A (ko) 갑각류 알레르기 치료를 위한 핵산

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1253363

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180420